Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease

Overview of attention for article published in Antibiotics, July 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 3 news outlets

twitter: 8 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Stockwatch, 01 Aug 2024

PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Aug. 1, 2024 Newly published in the peer-reviewed journal Antibiotics, the 331-pa…

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Yahoo! Finance USA, 01 Aug 2024

Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary…

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

PR Newswire, 01 Aug 2024

Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.